Amgen Oncology is leading the development of novel therapies that specifically harness the body’s T cells, pioneering the first immuno-oncology program using a BiTE®, or bispecific T cell engager. Explore the world of BiTE® immunotherapy as Amgen scientists Dr. Dirk Nagorsen and Dr. Peter Kufer discuss the current cancer treatment landscape, explain how BiTE® works and offer a preview of how Amgen is bringing this technology into the future of cancer treatment.